Latest News and Press Releases

– Four Abstracts Selected for Poster Presentations – – Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076 – ...

WATERTOWN, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening...

WATERTOWN, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

– Phase 3 IGNITE4 Results in Complicated Intra-Abdominal Infection Recognized as a ‘Best Rated Abstract’ – – Other Key Eravacycline and TP-6076 Data to Also be Highlighted – WATERTOWN, Mass., April ...

WATERTOWN, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...

WATERTOWN, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...

Achieved positive results of Eravacycline in Phase 3 IGNITE 4 clinical trial for cIAI  Filed NDA in US for IV Eravacycline for cIAI and PDUFA date is August 28th Raised over $65 million through...

WATERTOWN, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

WATERTOWN, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...